Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on […]

Read more

Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America

Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires, Argentina, September 2, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian company focused on innovative products with high quality medicines and active pharmaceutical ingredients, committed to expand patient access, and Laboratorio Varifarma SA, […]

Read more